Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals Ltd 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if...
Read more
Lifeloc Technologies, Inc. (OTCID:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the first quarter ended March 31, 2026. First Quarter Financial Highlights Lifeloc posted quarterly net revenue of $2.294 million resulting in a quarterly net loss of $(153) thousand, or $(0.06) per diluted share. These results compare to net revenue of $2.277 million and...
Read more
IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that it will present new Tau-PET biomarker research at the 2026 Global Tau Conference, taking place May 14-15, 2026, at the Grand Hyatt Washington in Washington, D.C., and online. The poster presentation, titled "Shannon Entropy of Tau-PET Spreading Patterns Predict Alzheimer's...
Read more
Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF)(Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its second quarter and first half of fiscal 2026 ended March 31, 2026 ("Q2" and "H1"). Results for Q2 and H1 demonstrated early results of the Company's continuing work to rebuild revenues back to profitability following two client setbacks in mid-2025, with revenue growth of 5% in H1 compared to H2 fiscal 2025....
Read more
ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2026. First Quarter 2026 Highlights Reported first quarter revenue of $12.1 million, including $2.3 million of IRRAflow revenue, representing 43% overall growth and 16% year-over-year total organic growth compared...
Read more
ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that the Velocity Alpha® MR High Speed Surgical Drill System has received CE Marking in addition to the existing FDA 510(k) clearance in the United States. The Velocity Alpha MR High Speed Surgical Drill System is manufactured by German-based surgical equipment leader Adeor...
Read moreAs demand grows for more physiologically relevant research models in drug discovery, cell therapy, and translational medicine, primary cells are becoming increasingly important across life science research workflows. Compared with immortalized cell lines, primary cells more closely retain native biological characteristics, making them valuable tools for disease modeling, toxicity evaluation, biomarker studies, regenerative medicine, and...
Read more
Tex Cycle Technology (M) Berhad ("Tex Cycle" or the "Group"), an established waste management and recycling solutions provider, today held its 22nd Annual General Meeting ("AGM"), where shareholders approved all resolutions tabled. At the AGM, shareholders received the Audited Financial Statements for the financial year ended 31 December 2025, together with the Directors' Report and Auditors' Report. Shareholders also approved the payment of...
Read more
FluoGuide A/S (STO:FLUO) will publish its interim report for Q1 2026 on Wednesday, 27 May 2026. Later that day, CEO Morten Albrechtsen and CFO Ole Larsen will present the company's operational and financial results for Q1 2026 in a live webcast. The webcast is hosted and moderated by Cecilia Hallström, BioStock. The presentation will be followed by a live Q&A session, where questions can be asked during the event or submitted in advance by...
Read more
Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the quarter ended March 31, 2026 and provided a corporate update on the advancement of its innovative DNase oncology platform. Recent Highlights Generated robust translational data supporting the DNase I...
Read more
Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies, today announces that an abstract for its BEXMAB Phase 1/2 study has been accepted as a poster presentation at the European Hematology Association (EHA) 2026 Congress, taking place in Stockholm, Sweden, 11-14 June 2026. The BEXMAB study investigates bexmarilimab in combination with...
Read moreAI Maverick Intel, Inc. ("AIMV" or the "Company") today announced the issuance of 76,500,000 common shares to HEAL Group Holdings Inc. ("HEAL"), representing an initial tranche of the consideration shares issuable pursuant to the Right of First Refusal Agreement between the parties effective February 11, 2026 (the "ROFR Agreement"). As previously disclosed, AIMV has also exercised its right under the ROFR Agreement to acquire 100% of the issued...
Read more
BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV)(STO:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that new clinical data from its ongoing Phase 2a trial evaluating BI-1808, its novel anti-TNFR2 monoclonal antibody, in patients with advanced CTCL will be presented at the upcoming European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden. The data underscore BI-1808's...
Read more
BioInvent International (STO:BINV) - BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that it has been selected for a poster presentation of the BI-1206 triplet combination in relapsed/refractory non-Hodgkin's lymphoma (NHL) at the 31st European Hematology Association (EHA2026) Congress, taking place June 11-14, 2026 in Stockholm, Sweden. Poster...
Read more
As many of our shareholders are aware, OSR Holdings filed its Preliminary Proxy Statement on Schedule PRE 14A with the U.S. Securities and Exchange Commission on May 11, 2026. Given the proximity of our Nasdaq minimum bid compliance deadline, we believe it is important to provide direct and unambiguous transparency regarding our strategy. Notably, the PRE 14A did not include a proposal authorizing a reverse stock split. This was a deliberate...
Read more
enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), today announced that Robert Berman, Chief Executive Officer of enVVeno Medical participated in a Virtual Investor "What This Means" segment. As part of the segment, Mr. Berman discussed the Company's recent news announcing the U.S. Food and Drug Administration's (FDA) first-ever IDE approval awarded to enVVeno to proceed with a U.S. pivotal study of a non-surgical...
Read more
Repair Biotechnologies, Inc., a biotechnology company developing first-in-class therapies capable of rapidly regressing atherosclerotic plaque, today announced that the U.S. Food and Drug Administration (FDA) has granted eligibility for the Rare Disease Evidence Principles (RDEP) program for its investigational messenger RNA (mRNA) therapy, REP-0003, in the treatment of homozygous familial hypercholesterolemia (HoFH). REP-0003 was granted Orphan...
Read moreMindMaze Therapeutics, a pioneer in advanced neurotherapeutic technologies, and Vibra Healthcare, a leading provider of neurological care and rehabilitation services, today announced the signing of a definitive channel partnership agreement. The agreement follows the previously announced term sheet and formalizes Vibra's role as a strategic commercial partner to introduce MindMaze Therapeutics' FDA-cleared digital neurotherapeutics platform to...
Read more
AbTherx, Inc., a privately held biotechnology company focused on accelerating the discovery of next-generation antibody therapeutics, today announced that the first human antibody therapeutic derived from its Atlas™ Mouse platform entered Phase 1 clinical development in Q1 2026. The transition from company inception to clinical validation in under three years highlights the efficiency of the AbTherx discovery engine. This milestone provides the...
Read more
Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into nutraceuticals, novel medicines, and valuable chemicals - announced its graduation from the Shell GameChanger™ Accelerator, a multimillion-dollar, multiyear program developed in collaboration between Shell and the U.S. Department of Energy's National Laboratory of the Rockies (NLR). From 2023 to 2026, eXoZymes partnered with...
Read more
